ADVISORY

No. 181
February 12, 2018

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), Maryland Medicaid Pharmacy Program (MMPP) has developed the Maryland Medicaid Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.

Tamiflu® and its generic (oseltamivir) are Preferred on the

Maryland Medicaid Preferred Drug List

The Maryland Medicaid Pharmacy Program would like to inform you that, effective Tuesday, February 13, 2018, both brand Tamiflu® and its generic (oseltamivir) are preferred on the Maryland Medicaid Preferred Drug List (PDL). This change affects all strengths of Tamiflu® and oseltamivir capsules and oral suspension. Claims for brand Tamiflu® capsules and oral suspension must be submitted with DAW 6 and will be priced appropriately. Claims for brand Tamiflu® with any other DAW code will reject. A MDH Medwatch form will not be required.

Please refer to our website for a complete list of the PDL at the following link:

The PDL is also available on your desktop computer by accessing Formulary Navigator™ at www.mmppi.com